Scott A. Rediger
Chief Executive Officer
Founder/Co-Founder of 3 companies (Ovation Communications, Dantis, and Access Media 3) over the last 25 years, including Co-found of Visible Genomics. Scott has built companies from start-up operations to annual revenues of more than $50M, including successful fundraising activities of more than $125M of equity and $150M of debt. Throughout his career, Scott has focused on building and scaling companies with a strong focus on the customer experience, ensuring that a "customer first" mentality is built throughout the entire company. He has focused on building partner friendly organizations that prioritize openness and flexibility working with both businesses and consumers alike.
Steven Ferrucci, OD, FAAO
Chief Medical Advisor
Dr. Steven Ferrucci is currently Chief of Optometry at the Sepulveda VA Ambulatory Care Center and Nursing Home. He is also the Residency Director at his sight, and a Professor at the Southern California College of Optometry/Marshall B. Ketchum University. Dr. Ferrucci has lectured and published extensively, with a special interest in Diabetes, Diabetic Eye Disease, AMD, OCT and Fluorescein Angiography. He is a fellow in both the American Academy of Optometry and the Optometric Retinal Society, as well as Past President of the ORS.
Joe Boyd
Business Development Director and Adviser
With a distinguished career spanning over 20 years in the diagnostic, pharmaceutical, and medical device industries, Boyd brings a wealth of expertise and a proven track record of success to his new role. Throughout his career, Boyd has demonstrated his ability to build customized sales, marketing, and commercial operations, supporting companies of all sizes. He strongly believes in fostering strong partnerships for company growth and success, actively engaging with key medical leaders and customers globally to build mutually beneficial relationships that ultimately benefit patients and communities.
Piru Perampalam
Director of Bioinformatics and Science
Dr. Piru Perampalam is a distinguished biochemist and bioinformatics engineer with over a decade of experience in the biopharma industry, having worked at renowned companies such as Roche and Genentech. Holding a PhD in Biochemistry from Western University, Dr. Perampalam has a robust background in identifying disease mechanisms and developing genome-wide screens to identify biomarkers and therapeutic targets, including publishing papers describing multi-omics screening methods to identify diseases and biomarkers in cancer. His work includes creating gene panel tests for disease diagnosis and developing computational tools and algorithms for genomic data analysis. Additionally, Dr. Perampalam has pioneered the use of AI models to identify diseases and stratify patients for personalized therapy, driving forward the boundaries of biomedical research and personalized medicine.